Dementia behavioural symptoms acquire approved pharmacotherapy
Brexpiprazole approval for agitation in Alzheimer's dementia and follow-on programs are reshaping dementia behavioural symptom management.
Dementia behavioural symptoms (agitation, aggression, psychosis) have historically been managed off-label with antipsychotics carrying boxed warnings about increased mortality in dementia. Brexpiprazole now carries specific approval for agitation in Alzheimer's dementia, the first medicine with this indication. Follow-on programs (additional atypical antipsychotic indication expansions, novel mechanism classes) are in late-stage trials. The infrastructure question (long-term care, family support, behavioural intervention capacity) defines the addressable population.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.